Stock Initiation of the Day: Keryx Biopharma, GlaxoSmithKline, AstraZeneca, and Raptor Pharma

LONDON, December 6, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Thursday, December 05, 2013, the US equity market finished the day on a lower note. The S&P 500 ended the day at 1,785.03, down 0.43%; the Dow Jones Industrial Average closed at 15,821.51, down 0.43%; and the NASDAQ Composite finished at 4,033.17, down 0.12%. The S&P 500 Health Care Sector Index ended the day at 629.06, down 0.27%. The S&P 500 Pharmaceuticals Sub Industry Index edged 0.30% lower to close the day at 483.29, while the Biotechnology Industry Index closed at 2,750.26, up 0.59%. The major movers in the sector included Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), GlaxoSmithKline PLC (NYSE: GSK), AstraZeneca PLC (NYSE: AZN), and Raptor Pharmaceuticals Corporation (NASDAQ: RPTP). AAAResearchReports.com free coverage on KERX, GSK, AZN, and RPTP is available upon registration at:

http://www.aaaresearchreports.com/register/  

Keryx Biopharmaceuticals Inc.'s stock plummeted on Thursday, ending the day at $12.94, which is 11.85% lower than the previous day's closing price of $14.68. The company's shares fluctuated between $12.51 and $14.84 during the trading session. A total of 8.25 million shares were traded, which is above the daily average volume of 2.86 million. Despite Thursday's decline, the company's shares have surged 41.73% in the previous three months, outperforming the S&P 500, which has gained 7.85%, during the same period. Furthermore, Keryx Biopharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $11.51 and $8.94, respectively. Download free technical research on KERX by signing up at:

http://www.AAAResearchReports.com/KERX120613.pdf

Shares in GlaxoSmithKline PLC edged 0.21% higher on Thursday, even as the broader market posted losses. The company's shares ended the day at $52.22, after trading between $52.02 and $52.25. A total of 2.00 million shares were traded, which is below the daily average volume of 2.50 million. The company's shares have gained 1.54% in the previous three months, compared to a gain of 7.85% in the S&P 500 during the same period. Additionally, GlaxoSmithKline PLC's stock is trading above its 50-day and 200-day moving averages of $51.73 and $50.51, respectively. Register now and get access to free analysis on GSK at:

http://www.AAAResearchReports.com/GSK120613.pdf

AstraZeneca PLC's stock edged lower on Thursday, finishing the day at $56.22, down 0.90% from the previous day's closing price of $56.73. The company's shares vacillated between $56.15 and $56.97 during the trading session. A total of 4.40 million shares were traded, which is above the daily average volume of 1.46 million. Despite Thursday's pullback, the company's shares have gained 6.10% in the last one month and 14.43% in the previous three months, outperforming the S&P 500, which has gained 1.25% and 7.85%, during the respective periods. Moreover, AstraZeneca PLC's stock is trading above its 50-day and 200-day moving averages of $52.82 and $50.58, respectively. Sign up and read our complimentary report on AZN at:

http://www.AAAResearchReports.com/AZN120613.pdf

On Thursday, shares in Raptor Pharmaceuticals Corp. fell 0.57%, tracking losses in the broader market. The company's shares traded between $13.79 and $14.10 before ending the day at $13.91. A total of 0.20 million shares were traded, which is below the daily average volume of 0.89 million. The company's shares have lost 0.86% in the previous three trading sessions, compared to a loss of 0.88% in the S&P 500 during the same period. However, Raptor Pharmaceuticals Corp.'s stock is trading above its 50-day and 200-day moving averages of $13.87 and $9.89, respectively. The free report on RPTP can be downloaded by signing up now at:

http://www.AAAResearchReports.com/RPTP120613.pdf

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE AAA Research Reports

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED